Background: Duchenne muscular dystrophy is a muscle wasting disease caused by dystrophin gene mutations resulting in dysfunctional dystrophin protein. Autophagy, a proteolytic process, is impaired in dystrophic skeletal muscle though little is known about the effect of dystrophin deficiency on autophagy in cardiac muscle. We hypothesized that with disease progression autophagy would become increasingly dysfunctional based upon indirect autophagic markers. Methods: Markers of autophagy were measured by western blot in 7-week-old and 17-month-old control (C57) and dystrophic (mdx) hearts. Results: Counter to our hypothesis, markers of autophagy were similar between groups. Given these surprising results, two independent experiments were conducted using 14-month-old mdx mice or 10-month-old mdx/Utrn AE mice, a more severe model of Duchenne muscular dystrophy. Data from these animals suggest increased autophagosome degradation. Conclusion: Together these data suggest that autophagy is not impaired in the dystrophic myocardium as it is in dystrophic skeletal muscle and that disease progression and related injury is independent of autophagic dysfunction.
Introduction
Duchenne muscular dystrophy (DMD) is a muscle wasting disease caused by the absence of functional dystrophin protein. Dystrophin anchors the dystrophin-associated glycoprotein complex (DGC), which connects the extracellular matrix to the actin cytoskeleton. This sarcolemmal architecture is necessary for the DGC to function as a conduit of force transduction, to provide stability to the sarcolemma, and participate in intracellular signaling. 1 In addition to sarcolemmal instability, 2 dystrophin deficiency results in secondary cellular dysfunctions [3] [4] [5] [6] [7] [8] [9] and ultimately leads to loss of motor function, respiratory failure, and cardiac failure.
Autophagy functions as a homeostatic mechanism, in which lysosomes degrade autophagosomal cargo. 10, 11 Upon stimulation of autophagy, nucleation of a phagophore begins and matures to become an autophagosome, which packages tagged proteins, organelles, and other cellular components. Autophagosomes then fuse with lysosomes creating an autophagolysosome, in which the autophagosomal cargo is degraded. We recently demonstrated that in dystrophic skeletal muscle degradation of autophagosomes is impaired due, at least in part, to lysosomal insufficiency. 12 In other investigations, rapamycin was used to inhibit mTOR in the mdx model, which increased autophagic flux and partially corrected disease-related losses in skeletal and cardiac muscle function. 13, 14 That stimulation of autophagy in the dystrophic myocardium preserved function suggests that autophagy is impaired by dystrophin deficiency. Other models of cardiac injury have shown that dysfunctional autophagy contributes to disease-related injury, [15] [16] [17] although in limb-girdle muscular dystrophy dysfunctional autophagy was not apparent. 18 Importantly, the extent to which autophagy changes with progressive cardiac injury in DMD is unknown. Consequently, the purpose of this investigation was to determine the extent to which degradation of autophagosomes is altered by disease progression in dystrophic cardiac muscle. We hypothesized that degradation of autophagosomes would become increasingly dysfunctional with disease progression.
Methods

Animal treatment
All procedures were approved by the Institutional Animal Care and Use Committees at Iowa State University or Auburn University. In Experiment 1, 7 wk and 17 mo C57 (7 wk n ¼ 5; 17 mo n ¼ 3) and mdx (7 wk n ¼ 8; 17 mo n ¼ 8) male mice were sedated with tribromoethanol (0.15 ml/g) and sacrificed by cervical dislocation. In an independent experiment (Experiment 2), 14 mo C57 and mdx mice (n ¼ 7 per group) were sedated with isoflurane and sacrificed by cardiac excision. Before eight weeks of age, cardiac function has been found to be normal in mdx mice but progresses to cardiomyopathy by 10 months of age 19 ; therefore, 7 wk old mice were used to model early disease progression and 14-17 mo mice were used to model late disease progression. In Experiment 3, 10 mo male C57 and dystrophin deficient mice heterozygous for a utrophin mutation (mdx/Utrn AE ) (n ¼ 8 per group) were treated as in Experiment 2. As these mice also suffer from decreased utrophin abundance, they have a more severe pathology compared to age-matched mdx mice. Excised hearts from all mice were frozen and stored at À80 C for subsequent analyses. Previously published data from this animal cohort include a detailed histopathological examination of hearts for the C57, mdx, and mdx/Utrn AE mice. 20, 21 Data regarding skeletal muscle from these mice have also been previously published, 22, 23 including the effect of disease progression on markers of autophagy. 12 
Biochemistry
Protein from hearts was isolated and subjected to western blotting as previously described. 12, 20, 23 Briefly, cardiac muscle was powdered using a dry ice-chilled metal mortar and pestle, protein extracted and concentration measured, and loaded onto a 4-20% gradient gel (Lonza). After separation and transfer, membranes were stained with Ponceau stain to verify equal loading, blocked in 5% milk made in Tris buffered saline with 0.2% Tween20 (TBST) and incubated in primary antibody overnight at 4 C. Membranes were washed and secondary antibodies were applied for 1 h at room temperature. Dilutions of primary and secondary antibodies were used as follows from Cell Signaling Technology Inc. (Danvers, MA, USA), unless otherwise noted: AMP-activated protein kinase (AMPK) (product no. 5832, Primary (P) 1:1000 5% milk in TBST, Secondary (S) 1:2000 2.5% milk in TBST), phosphorylated (p) AMPK (T172) (product no. 2535, P 1:1000 in TBST, S 1:2000 5% milk in TBST), Unc-51 Like Autophagy Activating Kinase 1 (ULK) (product no. 8054, P 1:500 in TBST, S 1:500 in TBST), p-ULK1 (S555) (product no. 5869, P 1:500 1% milk in TBST, S 1:500 in TBST), phosphoinositide 3-kinases (PI3K) Class III (product no. 3358, P 1:1000 5% milk in TBST, S 1:1000 5% milk in TBST), beclin 1 (product no. 3495, P 1:750 5% milk in TBST, S 1:1000 in TBST), p-beclin 1 (S93) (product no. 14717, P 1:500 1% milk in TBST, S 1:500 in TBST), autophagy-related protein (ATG) 5 (product no. 9980, P 1:1000 5% milk in TBST, S 1:2000 5% milk in TBST), ATG5/12 (product no. 4180, P 1:1000 1% milk in TBST, S 1:2000 5% milk in TBST), ATG7 (product no. 2631, P 1:1000 in TBST, S1:2000 in TBST), light chain 3 (LC3) (product no. 12741, P 1:500 5% milk in TBST, S 1:2000 5% milk in TBST), sequestosome 1 (SQSTM1, p62) (Abcam, Cambridge, UK) (product no. EPR4844, P 1:500 5% milk in TBST, S 1:1000 5% milk in TBST). Species specific secondary antibodies were obtained from Cell Signaling Technology Inc. (product no. 7074S, Danvers, MA, USA). Clarity TM (BioRad, Hercules, CA, USA) enhanced chemiluminescence was applied to each membrane for approximately 7 min, and then films were developed in a dark room to visualize protein bands. Protein bands were quantified using Carestream densitometry software (Carestream Health, Inc., New Haven, CT).
qPCR
Quantitative PCR was used to evaluate Spstm1 (p62) transcript abundance. RNA was extracted from snap frozen, powdered tissue using TriZol (15596018, ThermoScientific) and RNeasy purification kit (Qiagen), then cDNA was reverse transcribed using QuantiTect Reverse Transcriptase Kit (205310, Qiagen). Manufacturers' protocols were followed except for use of random hexamers (51-0118-01, IDT Premade Primers) instead of the RT primer mix provided (Qiagen). Sqsmt1 (p62) was evaluated (Forward -5 0 tgtggtgggaactcgctataa-3 0 , Reverse -5 0 -cagcggctatgagagaagctat-3 0 ) and normalized to 18s (Forward -5 0 -ctctagataacctcgggccg-3 0 , Reverse -5 0 -gtcgggagtgggtaatttgc-3 0 ).
Statistics
In Experiment 1, a two-way analysis of variance was used to compare differences between 7 wk and 17 mo C57 and mdx mice groups with age and disease status as main effects followed by a Newman-Keul post hoc test when indicated. In Experiments 2 and 3, a Student's t-test was used to compare differences between groups. Significance was established at P < 0.05, a priori.
Results
Experiment 1: 7 wk and 17 mo C57 and mdx mice
In skeletal muscle from these mice we previously reported impaired degradation of autophagosomes due, at least in part, to a lysosomal insufficiency. 12 To assess the effects of disease severity on markers of autophagy in dystrophic hearts, markers of activation, autophagosome formation, and autophagosome degradation were measured. Relative protein abundance and phosphorylation of upstream autophagy activator AMPK at threonine 172 (p-AMPK (T172)) was similar between groups as was the ratio of phosphorylated to total AMPK protein ( Figure 1 ). ULK1 protein abundance was decreased as a function of dystrophin deficiency compared to healthy hearts ( Figure 2 ). Phosphorylation of ULK1 at serine 555 (p-ULK1 (S555)) was similar between groups as was p-ULK1 (S555)/ULK1 ratio. After activation by ULK1, beclin 1 binds with PI3K class III to initiate phagophore formation. 24 Relative protein abundance of PI3K class III, beclin 1, and p-beclin 1 (S93)/beclin 1 ratio were similar between groups, though relative abundance of p-beclin 1 increased as a function of age.
The maturation of a phagophore to an autophagosome is regulated by ATG proteins. Specifically, ATG5 and 12 form a complex that ultimately binds with ATG16L. ATG5 protein abundance was similar between groups and abundance of the ATG5/12 complex increased as a function of age but was independent of disease status (Figure 3 ). The lipidation of LC3I to LC3II suggests movement toward the formation of mature autophagosomes, thus the ratio of LC3II/I was used as a marker for autophagic maturation. LC3I, LC3II, and LC3II/I were similar between healthy and diseased groups, though LC3II protein abundance and LC3II/I ratio increased as a function of age ( Figure 4 ). Lastly, protein abundance of p62, an inverse correlate of autophagic degradation, 25 was similar between groups. Further, p62 transcript expression was measured and was also similar between groups.
Experiment 2: 14 mo C57 and mdx mice
We previously reported increased histological damage and declining cardiac function in dystrophic hearts 20 as well as substantial impairments to limb and diaphragmatic function in these animals. 22, 23 Biochemical findings from 14 mo hearts largely recapitulated findings from Experiment 1. Protein markers of autophagosome maturation, ATG5 and 7, were similar between groups. LC3I was also similar between groups; however, LC3II, a marker of autophagosome abundance, was decreased by 56% in mdx mice compared to C57 raising the possibility of increased degradation of autophagosomes (Table 1 ). p62 protein abundance was similar between groups.
Experiment 3: 10 mo C57 and mdx/Utrn AE mice
A common criticism of the mdx model is its mild phenotype. While our investigation deliberately used mice early in disease progression (7 wk) and with evident cardiomyopathy (14 and 17 mo), we also assessed autophagy in a more severe disease model that is dystrophin deficient and heterozygous for a utrophin mutation (mdx/Utrn AE ). We previously found that hearts from 10-month-old mdx/Utrn AE mice are severely damaged and demonstrate cardiac function decline compared to age-matched C57 mice. 21 Notably, beclin 1 protein abundance was decreased by 10% in mdx/Utrn AE compared to C57 mice but ATG5 and ATG7 were similar between groups ( Figure 5 ). Relative protein abundance of LC3I was similar between groups but LC3II and LC3II/I were significantly reduced by 50% suggestive of increased degradation of autophagosomes. Lastly, p62 protein abundance was similar between groups.
Discussion
DMD is caused by the absence of dystrophin protein and collapse of the DGC. Dystrophic muscle cells are susceptible to contraction-induced injury resulting in secondary effects such as sarcolemma injury and cell degeneration. 26 The application of advanced respiratory support therapies now prolongs life in those with DMD to the extent that cardiomyopathy is an emergent threat facing these patients. Recent evidence indicates that several cardioprotective drugs 27 and nutraceuticals. 20, 21, 28 attenuate the severity of cardiomyopathy. Recently, autophagy has been identified as a target for pharmacological manipulation as autophagy is blunted in dystrophic skeletal muscle serving to limit removal of protein aggregates and damaged organelles. 12, 14 Pleiotropic therapeutics, such as mTOR inhibitors, which may, among other effects, activate autophagy, have successfully decreased disease severity in dystrophic skeletal and cardiac muscle 13, 14 ; however, the role of autophagy in progressive cardiomyopathy is unknown. We hypothesized that with advancing cardiac injury autophagy would exhibit markers of progressive dysfunction. On the whole, markers of autophagy were similar between healthy and diseased hearts at 7 wk and 17 mo of age, suggesting that autophagy is independent of disease-related injury to the myocardium. As these results were quite unexpected and there were numerical changes in several key variables, particularly with advanced disease, we carried out two additional confirmatory experiments. In the first confirmatory experiment using 14 mo mice, LC3II protein abundance decreased and p62 was similar in diseased hearts compared to healthy, raising the possibility that degradation of autophagosomes is enhanced in dystrophic cardiac muscle as autophagosomes are being degraded rapidly resulting in decreased LC3II. Further supporting this notion, LC3II abundance was decreased without alteration in p62 in 10 mo mdx/ Utrn AE mice compared to healthy. Given findings from Experiments 2 and 3, data from Experiment 1, in which LC3II and LC3II/I ratio were numerically decreased without a change in p62, could be supportive of increased degradation of autophagosomes, particularly in aged mice. Collectively these findings are interesting and raise novel insights into the nuanced role of autophagy and disease progression in dystrophic hearts.
Based on our preliminary interpretation of these findings, the reader should be aware that conclusions are tempered to match study design limitations. Specifically, the current approach relied upon archived samples, and as such, measures of autophagic flux were not immediately feasible. An alternative interpretation of these findings does not exclude the possibility that autophagy is impaired in dystrophic hearts. If autophagy were impaired, a reduction in LC3II could reflect decreased autophagosome formation and reduced efficiency of autophagosome degradation as suggested by similar p62. However, published findings likely do not support the notion of decreased autophagic flux in that a well-designed study focused on dystrophic hearts clearly delineated that LC3II increased following inhibition of autophagic degradation with chloroquine, indicative of increased flux. 29 In combination with outcomes in the current investigation, these findings suggest an increased flux accompanies disease progression. Indeed, careful scrutiny of work by Kang et al. indicates that autophagy increased following isolation of cardiomyocytes, which the authors attributed to cellular stress caused specifically by isolation. 29 An important extension of this point is that despite increased autophagy as a result of dystrophinopathy, cells were able to further increase autophagy suggesting it could be responsive to therapeutics intended to stimulate autophagy. In support, stimulation of autophagy via inhibition of mTOR was cardioprotective in 18 mo mdx mice. 13 Our first experiment also provides a limited opportunity to consider the effect of aging on markers of autophagy in healthy hearts. Here, we found that p-beclin and the ATG12/5 complex were increased as a function of age suggesting increased activation of autophagy. We also discovered increased LC3II and LC3II/I without a corresponding change in p62. Accumulation of LC3II can be due to either an increase in formation of autophagosomes, or a failure to degrade autophagosomes, or a combination of the two. As LC3II increased without a corresponding increase in p62 it is suggestive of increased degradation of autophagosomes in hearts from 17 mo mice compared to 7 wk old mice. Such findings are consistent with aging studies using pathway biomarkers of mice of similar age 30 ; however, in older mice autophagic dysfunction is apparent. [31] [32] [33] [34] In total, and counter to our hypothesis, indices of autophagic dysregulation were not evident in dystrophic hearts examined in these experiments. We interpret this finding to be particularly important in that the emergent understanding of autophagy in various cardiomyopathies, including dystrophic heart failure, is more nuanced and contextual than initially thought. 16, 17 Indeed, findings from the current investigation include hearts from several mouse cohorts that exhibited significant evidence of histochemical and physiological pathology. 20, 21 As such, these initial experiments to probe autophagy in dystrophic hearts suggest that despite disease progression, markers of autophagic activation and degradation appear to be independent of disease-related cardiomyopathy in the dystrophic myocardium. Moreover, our collective evidence is interpreted within the current literature, 29 which suggests autophagy is enhanced in dystrophindeficient hearts. Given the pathologic intracellular environment of a dystrophin-deficient fiber and that (nonspecific) autophagy activators provided therapeutic benefits, 13 cellular activators of autophagy may represent druggable targets leading to cardioprotection.
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